Cargando…

Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. The high risk of recurrence following surgical resection provides the rationale for adjuvant therapy. However, only a subset of patients benefit from adjuvant therapy. Identification of molecular markers to predict treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hwang, Jin-Hyeok, Voortman, Johannes, Giovannetti, Elisa, Steinberg, Seth M., Leon, Leticia G., Kim, Yong-Tae, Funel, Niccola, Park, Joo Kyung, Kim, Min A., Kang, Gyeong Hoon, Kim, Sun-Whe, Chiaro, Marco Del, Peters, Godefridus J., Giaccone, Giuseppe
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871055/ https://www.ncbi.nlm.nih.gov/pubmed/20498843 http://dx.doi.org/10.1371/journal.pone.0010630

Ejemplares similares

Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma
por: Maftouh, Mina, et al.
Publicado: (2014)

3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma
por: Cascioferro, Stella, et al.
Publicado: (2020)

hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
por: Meijer, Laura L., et al.
Publicado: (2016)

Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer
por: Massihnia, Daniela, et al.
Publicado: (2017)

Fungal mycobiome-mediated immune response: a non-negligible promoter in pancreatic oncogenesis and chemoresistance
por: Jiang, Yaling, et al.
Publicado: (2023)

Pancreatic Cancer
por: Funel, Niccola, et al.
Publicado: (2015)

AKT1 and SELP Polymorphisms Predict the Risk of Developing Cachexia in Pancreatic Cancer Patients
por: Avan, Abolfazl, et al.
Publicado: (2014)

High-Throughput MicroRNA (miRNAs) Arrays Unravel the Prognostic Role of MiR-211 in Pancreatic Cancer
por: Giovannetti, Elisa, et al.
Publicado: (2012)

Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing
por: Rovithi, Maria, et al.
Publicado: (2017)

Molecular Mechanisms Underlying the Role of MicroRNAs in the Chemoresistance of Pancreatic Cancer
por: Garajová, Ingrid, et al.
Publicado: (2014)

Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds
por: Li Petri, Giovanna, et al.
Publicado: (2020)

Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells
por: Firuzi, Omidreza, et al.
Publicado: (2019)

5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer
por: Toffalorio, Francesca, et al.
Publicado: (2018)

Metabolic Effects of New Glucose Transporter (GLUT-1) and Lactate Dehydrogenase-A (LDH-A) Inhibitors against Chemoresistant Malignant Mesothelioma
por: Franczak, Marika A., et al.
Publicado: (2023)

SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance
por: Randazzo, Ornella, et al.
Publicado: (2021)

c-Met as a Target for Personalized Therapy
por: Garajová, Ingrid, et al.
Publicado: (2015)

Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective
por: Ciccolini, Joseph, et al.
Publicado: (2016)

Role of Akt signaling in resistance to DNA-targeted therapy
por: Avan, Abolfazl, et al.
Publicado: (2016)

Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?
por: Peters, Godefridus J., et al.
Publicado: (2019)

MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma—a step towards personalized therapy
por: Garajová, Ingrid, et al.
Publicado: (2015)

USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy
por: García-Santisteban, Iraia, et al.
Publicado: (2013)

Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma
por: Vahabi, Mahrou, et al.
Publicado: (2023)

Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib
por: Muller, Ittai B, et al.
Publicado: (2017)

CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage
por: El Hassouni, Btissame, et al.
Publicado: (2019)

Redox-Mediated Mechanism of Chemoresistance in Cancer Cells
por: Kim, Eun-Kyung, et al.
Publicado: (2019)

Paradigm shift for defining the resectability of pancreatic cancer
por: Kang, Mee Joo, et al.
Publicado: (2021)

Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma
por: Sciarrillo, Rocco, et al.
Publicado: (2018)

Comment on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis
por: Che, Pei Pei, et al.
Publicado: (2020)

Pancreatoduodenectomy without Vascular Resection in Patients with Primary Resectable Adenocarcinoma and Unilateral Venous Contact: A Matched Case Study
por: Morelli, Luca, et al.
Publicado: (2018)

Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment
por: You, Min Su, et al.
Publicado: (2019)

Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report
por: Voortman, Jens, et al.
Publicado: (2006)

Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: Which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study
por: Lim, Kyu-Hyoung, et al.
Publicado: (2009)

Tissue microarray-chip featuring computerized immunophenotypical characterization more accurately subtypes ampullary adenocarcinoma than routine histology
por: Palmeri, Matteo, et al.
Publicado: (2020)

Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
por: Lee, Kyung-Hun, et al.
Publicado: (2021)

New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?
por: Van Der Steen, Nele, et al.
Publicado: (2016)

Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models
por: Che, Pei Pei, et al.
Publicado: (2020)

Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer
por: Ha, Hye rim, et al.
Publicado: (2016)

Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
por: Comandatore, Annalisa, et al.
Publicado: (2022)

Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma
por: Kim, Tae Hyun, et al.
Publicado: (2019)

The Role of ROR1 in Chemoresistance and EMT in Endometrial Cancer Cells
por: Lee, Kyung-Jun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ah1b86mittcv8rc7g329tl2ikn